D imaging and organoid models are revolutionizing dementia research, offering deeper insights into disease mechanisms and ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

I have a special interest in Alzheimer’s disease. For nearly 25 years, I practiced general neurology in Portland, Oregon, and ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

The era of targeting these proteins at an early stage to minimise risk of Alzheimer’s progressing has started. The prospect ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

A trial to identify fast and accurate blood tests that can diagnose dementia comes at an "exciting" time in the treatment of ...

Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's <a target=_blank href= ...

AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava”, the "Company”), a ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment inclu ...

Just 2.1 per cent of people with dementia undergo specialist investigations – such as having MRI or PET scans, which would be required for treatment with the breakthrough drugs lecanemab and ...